kabutan

STELLA PHARMA CORPORATION(4888) Summary

4888
TSE Growth
STELLA PHARMA CORPORATION
340
JPY
+48
(+16.44%)
Jan 29, 1:39 pm JST
2.22
USD
Jan 28, 11:39 pm EST
Result
PTS
outside of trading hours
341.1
Jan 29, 1:39 pm JST
Summary Chart Historical News Financial Result
PER
PBR
3.99
Yield
ー%
Margin Trading Ratio
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
284 JPY 1.85 USD
Previous Close Jan 28
292 JPY 1.91 USD
High Jan 29, 10:10 am
372 JPY 2.43 USD
Low Jan 29, 9:09 am
271 JPY 1.76 USD
Volume
9,860,800
Trading Value
3.49B JPY 0.02B USD
VWAP
353.61 JPY 2.31 USD
Minimum Trading Value
34,000 JPY 222 USD
Market Cap
0.01T JPY 0.08B USD
Number of Trades
9,234
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
Slightly High
1-Year Average
527
1-Year High Jan 27, 2026
10,676
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 0 2,172,400
Jan 16, 2026 0 2,193,200
Jan 9, 2026 0 2,297,900
Dec 26, 2025 0 1,831,800
Dec 19, 2025 0 1,902,500
Company Profile
STELLA PHARMA CORPORATION is a subsidiary of Stella Chemifa. The company develops, manufactures, and sells boron-based pharmaceuticals for cancer radiotherapy.
Sector
Pharmaceuticals
STELLA PHARMA CORPORATION is a biotech venture company within the Stella Chemifa group. It specializes in the development, manufacturing, and sales of "Steboronine," a boron-based pharmaceutical for cancer radiotherapy. The company has obtained the world's first approval for a drug used in Boron Neutron Capture Therapy (BNCT). Steboronine has been launched in Japan for the treatment of unresectable locally advanced or locally recurrent head and neck cancer. Clinical trials are currently underway to expand its applications to recurrent malignant glioma and recurrent high-grade meningioma. Leveraging its strength in high-purity boron-10 enrichment technology, STELLA PHARMA CORPORATION aims to expand its business both domestically and internationally.